PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of bttDove Medical PressThis ArticleSubscribeSubmit a ManuscriptSearchFollowDovepressBiologics: Targets and Therapy
 
From:
Published online 2012 July 2. doi: 10.2147/BTT.S20659

Table 3

Odds of progression of radiographic damage ranked by effect size: therapy plus methotrexate versus methotrexate

AgentTrialTreatment*Placebo*OR (95% CI)
InfliximabBreedveld et al1424%83%0.07 (0.02, 0.29)
Lipsky et al1311%31%0.26 (0.14, 0.50)
Pooled0.19 (0.09, 0.41)
EtanerceptKlareskog et al620%43%0.34 (0.21, 0.54)
Emery et al720%41%0.36 (0.23, 0.56)
Pooled0.35 (0.26, 0.47)
TocilizumabKremer et al1916%33%0.39 (0.25, 0.62)
AdalimumabBreedveld et al1236%63%0.33 (0.22, 0.51)
Keystone et al1138%54%0.52 (0.33, 0.83)
Pooled0.41 (0.27, 0.64)
Certolizumab pegolKeystone et al831%48%0.48 (0.34, 0.69)
Keystone et al926%41%0.51 (0.35, 0.75)
Pooled0.50 (0.38, 0.64)
RituximabCohen et al1643%61%0.48 (0.33, 0.71)
Tak et al1736%47%0.64(0.44, 0.93)
Pooled0.57 (0.43, 0.76)
GolimumabEmery et al1531%40%0.64 (0.44, 0.94)
AbataceptWesthovens et al2139%47%0.71 0.49, 1.03)

Note:

*Treatment refers to biologic DMARD plus methotrexate while placebo refers to the methotrexate plus placebo group. Bold text indicates pooled results for each agent.

Abbreviations: CI, confidence interval; DMARD, disease-modifying anti-rheumatic drug; OR, odds ratio.